Literature DB >> 35233758

The role of KMT2 gene in human tumors.

Zhi-Long Zhang1,2, Peng-Fei Yu3, Zhi-Qiang Ling4.   

Abstract

Histone methylation plays a crucial role in the regulation of gene transcriptional expression, and aberration of methylation-modifying enzyme genes can lead to a variety of genetic diseases, including human cancers. The histone modified protein KMT2 (lysin methyltransferase) family are involved in cell proliferation, growth, development and differentiation through regulating gene expression, and are closely related with many blood cancers and solid tumors. In recent years, several studies have shown that mutations in the KMT2 gene occur frequently in a variety of human cancers and the mutation status of the KMT2 gene may be correlated with the occurrence, development and prognosis of some tumors. Research uncovering the clinical characteristics and molecular mechanisms of KMT2 mutation in human tumors will be helpful for early diagnosis and prognosis of tumors as well as drug development for targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35233758     DOI: 10.14670/HH-18-447

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  63 in total

1.  Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

Authors:  Arnaud Augert; Qing Zhang; Breanna Bates; Min Cui; Xiaofei Wang; Gary Wildey; Afshin Dowlati; David MacPherson
Journal:  J Thorac Oncol       Date:  2016-12-19       Impact factor: 15.609

2.  Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.

Authors:  Xiaoqing Chen; Guochun Zhang; Bo Chen; Yulei Wang; Liping Guo; Li Cao; Chongyang Ren; Lingzhu Wen; Ning Liao
Journal:  Biomed Pharmacother       Date:  2019-05-27       Impact factor: 6.529

3.  Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study.

Authors:  Miryam Carecchio; Federica Invernizzi; Paulina Gonzàlez-Latapi; Celeste Panteghini; Giovanna Zorzi; Luigi Romito; Vincenzo Leuzzi; Serena Galosi; Chiara Reale; Federica Zibordi; Agnel P Joseph; Maya Topf; Carla Piano; Anna Rita Bentivoglio; Floriano Girotti; Paolo Morana; Benedetto Morana; Manju A Kurian; Barbara Garavaglia; Niccolò E Mencacci; Steven J Lubbe; Nardo Nardocci
Journal:  Mov Disord       Date:  2019-06-19       Impact factor: 10.338

4.  KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition.

Authors:  Soo-Jeong Cho; Changhwan Yoon; Jun Ho Lee; Kevin K Chang; Jian-Xian Lin; Young-Ho Kim; Myeong-Cherl Kook; Bülent Arman Aksoy; Do Joong Park; Hassan Ashktorab; Duane T Smoot; Nikolaus Schultz; Sam S Yoon
Journal:  Clin Cancer Res       Date:  2018-08-14       Impact factor: 12.531

5.  Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.

Authors:  Antao Chang; Liang Liu; Justin M Ashby; Dan Wu; Yanan Chen; Stacey S O'Neill; Shan Huang; Juan Wang; Guanwen Wang; Dongmei Cheng; Xiaoming Tan; W J Petty; Boris C Pasche; Rong Xiang; Wei Zhang; Peiqing Sun
Journal:  Cancer Res       Date:  2021-04-14       Impact factor: 12.701

6.  High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma.

Authors:  Abulajiang Abudureheman; Julaiti Ainiwaer; Zhichao Hou; Madiniyat Niyaz; Abdugheni Turghun; Ayshamgul Hasim; Haiping Zhang; Xiaomei Lu; Ilyar Sheyhidin
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-12       Impact factor: 4.553

7.  Expanding the neurodevelopmental phenotypes of individuals with de novo KMT2A variants.

Authors:  Ada J S Chan; Cheryl Cytrynbaum; Ny Hoang; Patricia M Ambrozewicz; Rosanna Weksberg; Irene Drmic; Anne Ritzema; Russell Schachar; Susan Walker; Mohammed Uddin; Mehdi Zarrei; Ryan K C Yuen; Stephen W Scherer
Journal:  NPJ Genom Med       Date:  2019-04-26       Impact factor: 8.617

8.  Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo.

Authors:  K I Ansari; S Kasiri; S S Mandal
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

9.  KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.

Authors:  Hunain Alam; Ming Tang; Mayinuer Maitituoheti; Shilpa S Dhar; Manish Kumar; Chae Young Han; Chandrashekar R Ambati; Samir B Amin; Bingnan Gu; Tsai-Yu Chen; Yu-Hsi Lin; Jichao Chen; Florian L Muller; Nagireddy Putluri; Elsa R Flores; Francesco J DeMayo; Laura Baseler; Kunal Rai; Min Gyu Lee
Journal:  Cancer Cell       Date:  2020-04-02       Impact factor: 38.585

10.  Childhood-onset dystonia-causing KMT2B variants result in a distinctive genomic hypermethylation profile.

Authors:  Andrea Ciolfi; Aidin Foroutan; Alessandro Capuano; Lucia Pedace; Lorena Travaglini; Simone Pizzi; Marco Andreani; Evelina Miele; Federica Invernizzi; Chiara Reale; Celeste Panteghini; Maria Iascone; Marcello Niceta; Ralitza H Gavrilova; Laura Schultz-Rogers; Emanuele Agolini; Maria Francesca Bedeschi; Paolo Prontera; Matteo Garibaldi; Serena Galosi; Vincenzo Leuzzi; Paola Soliveri; Rory J Olson; Giovanna S Zorzi; Barbara M Garavaglia; Marco Tartaglia; Bekim Sadikovic
Journal:  Clin Epigenetics       Date:  2021-08-11       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.